research update
-
Research updates, November 18
A new mechanistic study in Science Translational Medicine identifies Epstein-Barr virus (EBV) as a potential trigger of the autoimmune disease systemic lupus erythematosus.
-
Live blog: PolyBio’s Fall 2025 Symposium shares Long COVID and related disease research updates
Leading Long COVID and related disease researchers are set to present updates to their work today at the PolyBio Research Foundation’s Fall 2025 Symposium. PolyBio supports some of the most highly-anticipated research projects in infection-associated chronic conditions (IACCs).
-
Research updates, November 11
The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating Long COVID. The National Institutes of Health (NIH) study included 328 people who underwent interventions of either online cognitive training (computer games), a cognitive rehabilitation program, or received electric currents on their heads.
-
Research updates, November 4
The German government is cutting millions of euros in Long COVID funding, according to the German business newspaper Handelsblatt.
-
Research updates, October 28
A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in COVID-19. Researchers assessed over 70,000 blood cells from eight participants across different disease states.
-
Research updates, October 21
A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks.
-
Research updates, October 14
A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer.
-
Research updates, October 7
A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week.
-
Research updates, September 30
Researchers in Spain assessed over 190,000 participants, using data from a public health research network, in a study published in the journal Vaccines. They found that Long COVID prevalence was three to 10 times higher in individuals with three or more reported infections than in those with only one infection.
-
Research updates, September 23
Two recent studies found limitations of the drug Paxlovid for protection from Long COVID, contrasting prior studies that suggested the antiviral drug might help prevent this disease.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance